BR112022009331A2 - Formas cristalinas do receptor de quimiocina c c antagonista tipo 4 e usos das mesmas - Google Patents

Formas cristalinas do receptor de quimiocina c c antagonista tipo 4 e usos das mesmas

Info

Publication number
BR112022009331A2
BR112022009331A2 BR112022009331A BR112022009331A BR112022009331A2 BR 112022009331 A2 BR112022009331 A2 BR 112022009331A2 BR 112022009331 A BR112022009331 A BR 112022009331A BR 112022009331 A BR112022009331 A BR 112022009331A BR 112022009331 A2 BR112022009331 A2 BR 112022009331A2
Authority
BR
Brazil
Prior art keywords
crystalline forms
chemokine
receptor
antagonist
antagonist type
Prior art date
Application number
BR112022009331A
Other languages
English (en)
Inventor
J Arnold David
Robles Omar
E Rudisill Duane
J Wustrow David
Zibinsky Mikhail
Karaborni Sami
Original Assignee
Rapt Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rapt Therapeutics Inc filed Critical Rapt Therapeutics Inc
Publication of BR112022009331A2 publication Critical patent/BR112022009331A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

FORMAS CRISTALINAS DO RECEPTOR DE QUIMIOCINA C-C ANTAGONISTA TIPO 4 E USOS DAS MESMAS. São fornecidas formas cristalinas de um antagonista do receptor de quimiocina C-C tipo 4 (CCR4), formas de dosagem oral das mesmas e métodos de uso e preparação das mesmas.
BR112022009331A 2019-11-13 2020-11-13 Formas cristalinas do receptor de quimiocina c c antagonista tipo 4 e usos das mesmas BR112022009331A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962935007P 2019-11-13 2019-11-13
PCT/US2020/060575 WO2021097339A1 (en) 2019-11-13 2020-11-13 Crystalline forms of c-c chemokine receptor type 4 antagonist and uses thereof

Publications (1)

Publication Number Publication Date
BR112022009331A2 true BR112022009331A2 (pt) 2022-08-09

Family

ID=73856569

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022009331A BR112022009331A2 (pt) 2019-11-13 2020-11-13 Formas cristalinas do receptor de quimiocina c c antagonista tipo 4 e usos das mesmas

Country Status (12)

Country Link
EP (1) EP4058456A1 (pt)
JP (1) JP2023501584A (pt)
KR (1) KR20220101099A (pt)
CN (1) CN114728972A (pt)
AU (1) AU2020383625A1 (pt)
BR (1) BR112022009331A2 (pt)
CA (1) CA3158521A1 (pt)
IL (1) IL292755A (pt)
MX (1) MX2022005795A (pt)
TW (1) TW202132303A (pt)
WO (1) WO2021097339A1 (pt)
ZA (1) ZA202204943B (pt)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4911920A (en) 1986-07-30 1990-03-27 Alcon Laboratories, Inc. Sustained release, comfort formulation for glaucoma therapy
FR2588189B1 (fr) 1985-10-03 1988-12-02 Merck Sharp & Dohme Composition pharmaceutique de type a transition de phase liquide-gel
DE3815221C2 (de) 1988-05-04 1995-06-29 Gradinger F Hermes Pharma Verwendung einer Retinol- und/oder Retinsäureester enthaltenden pharmazeutischen Zubereitung zur Inhalation zur Einwirkung auf die Schleimhäute des Tracheo-Bronchialtraktes einschließlich der Lungenalveolen
JP2594486B2 (ja) 1991-01-15 1997-03-26 アルコン ラボラトリーズ インコーポレイテッド 局所的眼薬組成物
US5212162A (en) 1991-03-27 1993-05-18 Alcon Laboratories, Inc. Use of combinations gelling polysaccharides and finely divided drug carrier substrates in topical ophthalmic compositions
US5698155A (en) 1991-05-31 1997-12-16 Gs Technologies, Inc. Method for the manufacture of pharmaceutical cellulose capsules
EP1853260A1 (en) * 2005-02-16 2007-11-14 Merck & Co., Inc. Substituted pyrazoles as modulators of chemokine receptors
WO2010034740A1 (en) * 2008-09-23 2010-04-01 Palau Pharma, S.A. (r)-3-(n,n-dimethylamino)pyrrolidine derivatives
US8383812B2 (en) * 2009-10-13 2013-02-26 Bristol-Myers Squibb Company N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes
JP2013031931A (ja) * 2011-08-01 2013-02-14 Hitachi Koki Co Ltd 携帯式作業機
TW201311693A (zh) * 2011-09-02 2013-03-16 Kyowa Hakko Kirin Co Ltd 化學激活激素受體活性調節劑
AR096758A1 (es) * 2013-06-28 2016-02-03 Abbvie Inc Inhibidores cristalinos de bromodominios
KR102566924B1 (ko) * 2016-07-29 2023-08-11 랩트 테라퓨틱스, 인크. 케모카인 수용체 조절제 및 이의 용도
WO2018049271A1 (en) * 2016-09-09 2018-03-15 Flx Bio, Inc. Chemokine receptor modulators and uses thereof
BR112020004697A2 (pt) * 2017-09-12 2020-10-27 Ardea Biosciences, Inc. inibidores de cxcr-2 para tratamento de distúrbios
IL274444B1 (en) * 2017-11-06 2024-02-01 Rapt Therapeutics Inc Chemokine receptor modulators for the treatment of Epstein-Barr virus-positive cancer
CN109796457B (zh) * 2019-03-28 2020-03-06 苏州国匡医药科技有限公司 一种2-(3-(氮杂环丁烷-3-基)哌啶-1-基)乙基-1-醇的制备方法及其应用

Also Published As

Publication number Publication date
CA3158521A1 (en) 2021-05-20
MX2022005795A (es) 2022-06-08
KR20220101099A (ko) 2022-07-19
CN114728972A (zh) 2022-07-08
US20210139487A1 (en) 2021-05-13
TW202132303A (zh) 2021-09-01
JP2023501584A (ja) 2023-01-18
AU2020383625A1 (en) 2022-05-05
WO2021097339A1 (en) 2021-05-20
ZA202204943B (en) 2023-11-29
IL292755A (en) 2022-07-01
EP4058456A1 (en) 2022-09-21

Similar Documents

Publication Publication Date Title
CO2019002596A2 (es) Un esteroide 19-nor-c21-n-pirazolilo c3,3-disustituido cristalino
NI202000078A (es) Compuestos heteroaril tetracíclicos
JOP20210005A1 (ar) عوامل تحلل مستقبلات الإستروجين الانتقائية
CL2021000046A1 (es) Degradadores selectivos del receptor de estrógeno
BR112017025108A2 (pt) compostos seletivos de pyy e usos dos mesmos
BR112017007816A2 (pt) composições farmacêuticas compreendendo variantes de peptídeos e métodos de uso das mesmas
TW200635897A (en) Piperidine derivatives and their use as anti-inflammatory agents
CL2021001790A1 (es) Enlazadores sin trazas, conjugados de proteínas de los mismos y composiciones de los mismos
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
CO2019000945A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
BR112023000990A2 (pt) Formulações de esteroide c21-n-pirazolil 19-nor c3,3- dissubstituído e métodos de uso das mesmas
CO2019000943A2 (es) Moduladores del receptor nmda espiro-lactam y uso de los mismos
CO2021006482A2 (es) Ureas cíclicas
BR112017023147A2 (pt) azabenzimidazóis e seu uso como moduladores do receptor de ampa
NI201900080A (es) Moduladores del receptor de estrógeno
JOP20220160A1 (ar) مركبات فعّالة نحو مستقبلات نووية
PH12020550537A1 (en) Bicyclic sulfones and sulfoxides and methods of use thereof
MX2022007265A (es) Compuestos activos frente a receptores nucleares.
NO20052491D0 (no) Nye vitronektinresepotr antagonistderivater, fremgangsmate til deres fremstilling, anvendelse derav som legemidler og farmasoytiske sammensetninger som inneholder de samme
BR112022009331A2 (pt) Formas cristalinas do receptor de quimiocina c c antagonista tipo 4 e usos das mesmas
BR112022010143A2 (pt) Inibidores de ahr e usos respectivos
CL2017002605A1 (es) Derivados de indol
ITCR20040003A1 (it) Elettrostimolatore muscolare multiprogramma, con interfaccia di facile uso per la selezione del programma desiderato, e relativo metodo di s elezione
TR201914406A2 (tr) Sapropteri̇n di̇hi̇droklorür ve en az bi̇r farmasöti̇k eksi̇pi̇yan i̇çeren kati oral farmasöti̇k formülasyonlar
CR20190401A (es) Dropropizina en combinación con ambroxol en la forma farmacéutica de jarabe y tabletas